Alnylam Pharmaceuticals' Q2 2025: Unraveling Key Contradictions in AMVUTTRA's Market Strategy and Patient Access

Patient profile and prescriber base for AMVUTTRA, launch dynamics and access, patient mix for AMVUTTRA, payer coverage and access, and AMVUTTRA pricing are the key contradictions discussed in Alnylam Pharmaceuticals' latest 2025Q2 earnings call.



Strong TTR Franchise Performance:
- Alnylam's TTR franchise revenues reached $544 million in Q2 2025, representing 77% year-over-year growth.
- This performance was largely driven by the launch of AMVUTTRA for ATTR-CM.

AMVUTTRA Launch Success:
- The company closed the quarter with approximately 1,400 cardiomyopathy patients on therapy, contributing an estimated $150 million in revenue.
- The rapid uptake was due to strong execution, broad payer coverage, and physician adoption due to AMVUTTRA's differentiated profile.

Pivotal Pipeline Advancements:
- Alnylam initiated the TRITON-CM Phase III study for nucresiran, which offers greater knockdown and efficacy.
- This advancement is part of Alnylam's strategy to maintain leadership in TTR amyloidosis and expand its pipeline.

Financial Performance and Guidance Increase:
- Alnylam reported $672 million in total net product revenues, up 64% year-over-year.
- The company increased its total net product revenues guidance for 2025 to a revised range of $2.65 billion to $2.8 billion, reflecting confidence in the ATTR-CM launch and other commercial products.